Venova Medical is developing the velocity percutaneous arteriovenous fistula (pAVF) system to create AVFs for hemodialysis access. The velocity system is designed to reduce the need for reinterventions to achieve fistula maturation, improve vascular access outcomes, and lower costs. The company is conducting the prospective, single-center, single-arm VENOS-1 clinical trial (NCT05757726) evaluating the safety and feasibility of the velocity system in patients on hemodialysis. Venova intends to use new funding to support clinical studies of the velocity pAVF system in patients with chronic and end-stage renal disease. The company was co-founded by CEO Erik van der Burg and Shant Vartanian, MD, and recently appointed Darshana Zaveri of Catalyst Health Ventures to its board. Venova is based in Los Gatos, California.

Total raised

$30M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2024